2026 Global: Absorbable Heart Stent Market -Competitive Review (2032) report
Description
The 2026 Global: Absorbable Heart Stent Market-Competitive Review (2032) report features the global market size and projected growth/decline data for the period 2021 and 2032. The report primarily provides an examination of the business strategies for the ten largest global companies in the market and how their strategies differ.
Within the absorbable heart stent arena, Abbott Vascular, headquartered in Abbott Park, United States, led with the Absorb BVS, a landmark PLA-based scaffold introduced in the early 2010s to offer temporary vessel support followed by resorption. REVA Medical, based in San Diego, United States, pursued PLLA-based bioabsorbable scaffolds aimed at reducing late stent thrombosis risk and late lumen loss relative to permanent metal stents, advancing clinical evaluation during the mid-2010s. Lifetech Scientific Corporation, headquartered in Shenzhen, China, expanded its portfolio to include bioabsorbable scaffolds, leveraging regional trials and collaborations to explore PLLA and other resorbable polymers as alternatives to conventional permanent implants. The combined efforts of these firms illustrate the global exploration of resorbable technology, with R&D activities spanning North America, Europe, and Asia, as clinicians sought to modulate neointimal response and events. Regulatory review, safety signals, and long-term outcomes in registries have shaped the course of this technology, tempering the early optimism globally.
Meril Life Sciences, based in Mumbai, India, has invested in absorbable scaffold research, integrating it with a portfolio of interventional devices, while pursuing regulatory pathways across emerging markets. Biosensors International Holdings, headquartered in Singapore, Singapore, has contributed to the field through partnerships and device platforms that span drug-eluting and bioabsorbable concepts, reflecting a broader Asia-Pacific strategy. Elixir Medical, headquartered in Sunnyvale, United States, focused on next-generation scaffolds and polymer-based designs, exploring combinations of mechanical performance and biodegradation to enhance long-term vessel healing. These companies collectively reflect a multi-regional effort to identify materials, geometries, and drug-elution strategies that could deliver safety and efficacy advantages in the medium term. Regulatory reviews and patient safety surveillance in India, Singapore, and the United States shape the path to commercialization for absorbable stents, with post-market registries providing crucial feedback for iterative design. Cross-border collaboration accelerates knowledge transfer and equipment uptake across hospital networks globally.
Amaran Medical, headquartered in Santa Clara, United States, emerged as a newer entrant pursuing bioabsorbable scaffolds with next-generation manufacturing approaches, aiming to address manufacturing consistency and radiographic visibility. AnGes MG, Inc., based in Osaka, Japan, pursued bioabsorbable scaffold development within a broader portfolio of gene and non-viral delivery platforms, reflecting Japan's medical device ecosystem. Xeltis AG, located in Geneva, Switzerland, pursued bioabsorbable vascular scaffolds with a regenerative approach and polymer innovations intended to gradually replace stents with native tissue, representing a distinct pathway from conventional PLLA devices. Cordis, a Johnson & Johnson company headquartered in Bridgewater, United States, participated historically in transcatheter cardiovascular devices and engaged in research on resorbable technologies, though market deployment varied by region. The collective activity of these ten entities underscores the heterogeneity of design strategies—polymer composition, degradation timelines, scaffold geometry, and regulatory navigation—that have defined the absorbable heart stent landscape globally.
Within the absorbable heart stent arena, Abbott Vascular, headquartered in Abbott Park, United States, led with the Absorb BVS, a landmark PLA-based scaffold introduced in the early 2010s to offer temporary vessel support followed by resorption. REVA Medical, based in San Diego, United States, pursued PLLA-based bioabsorbable scaffolds aimed at reducing late stent thrombosis risk and late lumen loss relative to permanent metal stents, advancing clinical evaluation during the mid-2010s. Lifetech Scientific Corporation, headquartered in Shenzhen, China, expanded its portfolio to include bioabsorbable scaffolds, leveraging regional trials and collaborations to explore PLLA and other resorbable polymers as alternatives to conventional permanent implants. The combined efforts of these firms illustrate the global exploration of resorbable technology, with R&D activities spanning North America, Europe, and Asia, as clinicians sought to modulate neointimal response and events. Regulatory review, safety signals, and long-term outcomes in registries have shaped the course of this technology, tempering the early optimism globally.
Meril Life Sciences, based in Mumbai, India, has invested in absorbable scaffold research, integrating it with a portfolio of interventional devices, while pursuing regulatory pathways across emerging markets. Biosensors International Holdings, headquartered in Singapore, Singapore, has contributed to the field through partnerships and device platforms that span drug-eluting and bioabsorbable concepts, reflecting a broader Asia-Pacific strategy. Elixir Medical, headquartered in Sunnyvale, United States, focused on next-generation scaffolds and polymer-based designs, exploring combinations of mechanical performance and biodegradation to enhance long-term vessel healing. These companies collectively reflect a multi-regional effort to identify materials, geometries, and drug-elution strategies that could deliver safety and efficacy advantages in the medium term. Regulatory reviews and patient safety surveillance in India, Singapore, and the United States shape the path to commercialization for absorbable stents, with post-market registries providing crucial feedback for iterative design. Cross-border collaboration accelerates knowledge transfer and equipment uptake across hospital networks globally.
Amaran Medical, headquartered in Santa Clara, United States, emerged as a newer entrant pursuing bioabsorbable scaffolds with next-generation manufacturing approaches, aiming to address manufacturing consistency and radiographic visibility. AnGes MG, Inc., based in Osaka, Japan, pursued bioabsorbable scaffold development within a broader portfolio of gene and non-viral delivery platforms, reflecting Japan's medical device ecosystem. Xeltis AG, located in Geneva, Switzerland, pursued bioabsorbable vascular scaffolds with a regenerative approach and polymer innovations intended to gradually replace stents with native tissue, representing a distinct pathway from conventional PLLA devices. Cordis, a Johnson & Johnson company headquartered in Bridgewater, United States, participated historically in transcatheter cardiovascular devices and engaged in research on resorbable technologies, though market deployment varied by region. The collective activity of these ten entities underscores the heterogeneity of design strategies—polymer composition, degradation timelines, scaffold geometry, and regulatory navigation—that have defined the absorbable heart stent landscape globally.
Table of Contents
32 Pages
- 1.0 Scope of Report and Methodology
- 2.0 Market SWOT Analysis and Players
- 2.1 Market Definition
- 2.2 Market Segments
- 2.3 Market Strengths
- 2.4 Market Weaknesses
- 2.5 Market Threats
- 2.6 Market Opportunities
- 2.7 Major Players
- 3.0 Competitive Analysis
- 3.1 Market Player 1
- 3.2 Market Player 2
- 3.3 Market Player 3
- 3.4 Market Player 4
- 3.5 Market Player 5
- 3.6 Market Player 6
- 3.7 Market Player 7
- 3.8 Market Player 8
- 3.9 Market Player 9
- 3.10 Market Player 10
- 4.0 Comparative Business Strategies
- 4.1 Comparative Business Strategies of Player 1 and 2
- 4.2 Comparative Business Strategies of Player 1 and 3
- 4.3 Comparative Business Strategies of Player 1 and 4
- 4.4 Comparative Business Strategies of Player 2 and 3
- 4.5 Comparative Business Strategies of Player 2 and 4
- 4.6 Comparative Business Strategies of Player 3 and 4
- 5.0 Appendix
Search Inside Report
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
